Generate Biomedicines Doses First Patient in Phase 1 CAR T Trial

Generate Biomedicines has dosed the first patient in a Phase 1 trial of GB-5267, an IL-18—armored CAR T therapy targeting MUC16 in ovarian cancer. This marks an early-stage, first-in-human study for the company's AI-designed cell therapy.